Physician profile
Sungho K Cho
NPI 1932152360
$1,217.81
in general payments reported to CMS, 2019-2025
4 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $76.15 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,017 · Food and Beverage: $76.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,016.66 |
| Food and Beverage | $76.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $1,016.66 | 2025 | |
| Sarepta Therapeutics, INC. | $125.00 | 2022 | |
| Sk Life Science, INC. | $76.15 | 2023 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$97,935.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sungho Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.